Literature DB >> 11480719

Malignant pericardial effusion.

A García-Riego1, C Cuiñas, J J Vilanova.   

Abstract

OBJECTIVE: To examine the frequency and diagnostic implications of malignant pericardial effusions. STUDY
DESIGN: The clinical and histologic records of pericardial effusions diagnosed cytologically as malignant were reviewed. We investigated the relationship between malignancy and type of tumor, interval between diagnosis of the primary tumor and development of the pericardial effusion, and length of survival after the onset of the effusion.
RESULTS: There were 375 pericardial effusions among 23,592 effusions studied over 24 years; 65 of them were diagnosed as malignant. The mean age at onset was 53.6 years. In 92% of the cases the primary tumor was epithelial, lung the most frequent in males and breast in females. In 48% of cases the pericardial effusion constituted the first sign of malignancy.
CONCLUSION: Diagnosis of a pericardial effusion as malignant carried an ominous prognosis: 86% of patients died within the first year and nearly one-third within the first month. Breast carcinomas were linked with the longest survival and longest interval of latency prior to the onset of the pericardial effusion. There were two effusions associated with lymphoblastic lymphomas; they have had no recurrence 10 and 17 years after the effusion, and the patients can be considered cured.

Entities:  

Mesh:

Year:  2001        PMID: 11480719     DOI: 10.1159/000327865

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  6 in total

Review 1.  A Clinico-Pathologic Approach to the Differential Diagnosis of Pericardial Tumors.

Authors:  Alison R Krywanczyk; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

2.  Relapsing Multiple Myeloma Presenting as Cardiac Tamponade and Obstructive Uropathy.

Authors:  Bright E Izekor; Pruthali Kulkarni; Priscilla R Powell; James Hall; Rex C Garland
Journal:  Cureus       Date:  2021-04-15

3.  The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion.

Authors:  U Bildirici; U Celikyurt; E Acar; O Bulut; T Sahin; G Kozdag; D Ural
Journal:  Cardiovasc J Afr       Date:  2012-04       Impact factor: 1.167

4.  Clinical characteristics of malignant pericardial effusion associated with recurrence and survival.

Authors:  Sung-Hwan Kim; Mi Hyang Kwak; Sohee Park; Hak Jin Kim; Hyun-Sung Lee; Moon Soo Kim; Jong Mog Lee; Jae Ill Zo; Jung Sil Ro; Jin Soo Lee
Journal:  Cancer Res Treat       Date:  2010-12-31       Impact factor: 4.679

5.  Clinico-cytopathologic analysis of 574 Pericardial Effusion Specimens: Application of the international system for reporting serous fluid cytopathology (ISRSFC) and long-term clinical follow-up.

Authors:  Min Jeong Song; Uiree Jo; Ji-Seon Jeong; Kyung-Ja Cho; Gyungyub Gong; Yong Mee Cho; Joon Seon Song
Journal:  Cancer Med       Date:  2021-11-07       Impact factor: 4.452

Review 6.  The Value of Cytology in the Evaluation of Malignant Pericardial Effusions: A Systematic Review.

Authors:  Ranim Shartouni; Roy Shartouni; Maryam Mahmoodi; Ilias P Nikas
Journal:  Diagnostics (Basel)       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.